Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $450 to $380.
Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $450 to $380.